MetaVia Inc. (NASDAQ:MTVA) Short Interest Update

MetaVia Inc. (NASDAQ:MTVA) was the recipient of a large growth in short interest in the month of January. As of January 15th, there was short interest totaling 163,195 shares, a growth of 729.1% from the December 31st total of 19,683 shares. Currently, 7.5% of the shares of the company are sold short. Based on an average trading volume of 234,028 shares, the days-to-cover ratio is currently 0.7 days. Based on an average trading volume of 234,028 shares, the days-to-cover ratio is currently 0.7 days. Currently, 7.5% of the shares of the company are sold short.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on the stock. Wall Street Zen upgraded shares of MetaVia from a “sell” rating to a “hold” rating in a research note on Saturday, January 17th. HC Wainwright boosted their target price on shares of MetaVia from $12.00 to $40.00 and gave the stock a “buy” rating in a research note on Tuesday, January 6th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of MetaVia in a report on Monday, December 22nd. Two analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, MetaVia currently has an average rating of “Hold” and a consensus target price of $36.50.

Institutional Trading of MetaVia

An institutional investor recently bought a new position in MetaVia stock. Virtu Financial LLC bought a new position in MetaVia Inc. (NASDAQ:MTVA) in the 3rd quarter, according to its most recent disclosure with the SEC. The firm bought 32,755 shares of the company’s stock, valued at approximately $31,000. Virtu Financial LLC owned 0.14% of MetaVia at the end of the most recent quarter. 1.37% of the stock is owned by institutional investors.

MetaVia Stock Down 7.5%

Shares of MTVA traded down $0.21 during trading hours on Tuesday, hitting $2.60. The company had a trading volume of 262,674 shares, compared to its average volume of 234,655. The business has a fifty day moving average of $7.44 and a 200-day moving average of $8.47. The firm has a market cap of $5.72 million, a price-to-earnings ratio of -0.31 and a beta of 0.27. MetaVia has a 12 month low of $2.60 and a 12 month high of $23.54.

MetaVia (NASDAQ:MTVA) last announced its quarterly earnings data on Thursday, November 6th. The company reported ($1.54) earnings per share for the quarter, beating the consensus estimate of ($2.86) by $1.32. On average, equities analysts expect that MetaVia will post -3.9 EPS for the current fiscal year.

About MetaVia

MetaVia Inc is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc, formerly known as NeuroBo Pharmaceuticals Inc, is based in CAMBRIDGE, Mass.